Summit Therapeutics (SMMT) Stock Forecast, Price Target & Predictions

OverviewOwnership Financials Chart Transcripts

SMMT Stock Forecast

Summit Therapeutics stock forecast is as follows: an average price target of $35.00 (represents a 95.86% upside from SMMT’s last price of $17.87) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

SMMT Price Target

The average price target for Summit Therapeutics (SMMT) is $35.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $23.00. This represents a potential 95.86% upside from SMMT's last price of $17.87.

SMMT Analyst Ratings

Buy

According to 4 Wall Street analysts, Summit Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SMMT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Summit Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 04, 2024	Reni Benjamin	JMP Securities	$32.00	$19.96	60.32%	79.07%
Sep 27, 2024	Yigal Nochomovitz	Summit Redstone Partners	$23.00	$20.89	10.13%	28.71%
Sep 25, 2024	Brad Canino	Stifel Nicolaus	$40.00	$24.00	66.67%	123.84%
Sep 16, 2024	Mitchell Kapoor	H.C. Wainwright	$45.00	$31.93	40.93%	151.82%
Jun 03, 2024	Brad Canino	Stifel Nicolaus	$14.00	$8.69	61.20%	-21.66%
Mar 25, 2024	Brad Canino	Stifel Nicolaus	$8.00	$3.28	143.90%	-55.23%

The latest Summit Therapeutics stock forecast, released on Nov 04, 2024 by Reni Benjamin from JMP Securities, set a price target of $32.00, which represents a 60.32% increase from the stock price at the time of the forecast ($19.96), and a 79.07% increase from SMMT last price ($17.87).

Summit Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	3	6
Avg Price Target	-	$31.67	$27.00
Last Closing Price	$17.87	$17.87	$17.87
Upside/Downside	-100.00%	77.22%	51.09%

In the current month, the average price target of Summit Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Summit Therapeutics's last price of $17.87. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 11, 2024	Wells Fargo		Overweight	Initialise
Nov 18, 2024	H.C. Wainwright	Buy	Buy	Hold
Nov 04, 2024	JMP Securities		Market Outperform	Initialise
Oct 31, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 04, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 27, 2024	Citigroup	Buy	Neutral	Downgrade
Sep 09, 2024	Citigroup	Buy	Buy	Hold
Sep 03, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 12, 2024	H.C. Wainwright		Buy	Initialise
Jul 19, 2024	Citigroup	Buy	Buy	Hold
May 31, 2024	Citigroup	Buy	Buy	Hold
May 07, 2024	Citigroup		Buy	Initialise

Summit Therapeutics's last stock rating was published by Wells Fargo on Dec 11, 2024. The company Initialise its SMMT rating from "null" to "Overweight".

Summit Therapeutics Financial Forecast

Summit Therapeutics Revenue Forecast

	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 18	Sep 17
Revenue	-	-	-	-	-	-	-	-	-	$57.00K	$192.00K	$185.00K	$181.00K	$170.00K	$312.96K	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	$9.74M	$3.22M	$3.19M	$2.90M	$3.16M	$3.21M	$4.22M	$3.83M	$177.69K	$5.30M	$21.25M
High Forecast	-	-	-	-	-	-	-	-	$9.74M	$3.22M	$3.19M	$2.90M	$3.16M	$3.21M	$4.22M	$3.83M	$213.23K	$6.37M	$25.49M
Low Forecast	-	-	-	-	-	-	-	-	$9.74M	$3.22M	$3.19M	$2.90M	$3.16M	$3.21M	$4.22M	$3.83M	$142.15K	$4.24M	$17.00M
# Analysts	-	-	-	-	-	-	-	-	1	7	13	13	7	7	9	8	14	7	11
Surprise %	-	-	-	-	-	-	-	-	-	0.02%	0.06%	0.06%	0.06%	0.05%	0.07%	-	-	-	-

Summit Therapeutics's average Quarter revenue forecast for Dec 23 based on 1 analysts is $9.74M, with a low forecast of $9.74M, and a high forecast of $9.74M. SMMT's average Quarter revenue forecast represents a 16990.48% increase compared to the company's last Quarter revenue of $57.00K (Jun 21).

Summit Therapeutics EBITDA Forecast

	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 18	Sep 17
# Analysts	-	-	-	-	-	-	-	-	1	7	13	13	7	7	9	8	14	7	11
EBITDA	-	-	-	-	-	-	-	-	-	$-23.75M	$-17.00M	$-13.27M	$-17.34M	$-14.91M	$-6.90M	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	$-5.84M	$-9.46M	$-1.91M	$-1.74M	$-1.47B	$-1.93M	$-2.53M	$-2.30M	$-6.91M	$-8.64M	$11.09M
High Forecast	-	-	-	-	-	-	-	-	$-5.84M	$-7.57M	$-1.91M	$-1.74M	$-1.18B	$-1.93M	$-2.53M	$-2.30M	$-5.53M	$-6.91M	$13.31M
Low Forecast	-	-	-	-	-	-	-	-	$-5.84M	$-11.35M	$-1.91M	$-1.74M	$-1.77B	$-1.93M	$-2.53M	$-2.30M	$-8.30M	$-10.36M	$8.87M
Surprise %	-	-	-	-	-	-	-	-	-	2.51%	8.89%	7.63%	0.01%	7.74%	2.72%	-	-	-	-

undefined analysts predict SMMT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Summit Therapeutics's previous annual EBITDA (undefined) of $NaN.

Summit Therapeutics Net Income Forecast

	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 18	Sep 17
# Analysts	-	-	-	-	-	-	-	-	1	7	13	13	7	7	9	8	14	7	11
Net Income	-	-	-	-	-	-	-	-	-	$-25.10M	$-18.05M	$-13.44M	$-17.70M	$-15.28M	$-6.11M	-	-	-	-
Avg Forecast	$-463.08M	$-66.82M	$-57.28M	$-51.55M	$-45.82M	$-45.70M	$-36.25M	$-34.60M	$1.20B	$-9.72M	$-87.08M	$-109.19M	$-1.51B	$-51.11M	$-14.67M	$-118.98M	$-7.66M	$-7.99M	$12.24M
High Forecast	$-463.08M	$-66.82M	$-57.28M	$-51.55M	$-45.82M	$-39.99M	$-36.25M	$-34.60M	$1.20B	$-7.78M	$-87.08M	$-109.19M	$-1.20B	$-51.11M	$-14.67M	$-118.98M	$-6.12M	$-6.39M	$14.69M
Low Forecast	$-463.08M	$-66.82M	$-57.28M	$-51.55M	$-45.82M	$-51.42M	$-36.25M	$-34.60M	$1.20B	$-11.67M	$-87.08M	$-109.19M	$-1.81B	$-51.11M	$-14.67M	$-118.98M	$-9.19M	$-9.59M	$9.79M
Surprise %	-	-	-	-	-	-	-	-	-	2.58%	0.21%	0.12%	0.01%	0.30%	0.42%	-	-	-	-

Summit Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SMMT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Summit Therapeutics SG&A Forecast

	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 18	Sep 17
# Analysts	-	-	-	-	-	-	-	-	1	7	13	13	7	7	9	8	14	7	11
SG&A	-	-	-	-	-	-	-	-	-	$5.98M	$4.18M	$5.80M	$7.46M	$5.77M	$646.95K	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	$173.48M	$2.38M	$56.78M	$51.60M	$56.24M	$57.15M	$75.22M	$68.18M	$3.16M	$3.65M	$2.79M
High Forecast	-	-	-	-	-	-	-	-	$173.48M	$2.86M	$56.78M	$51.60M	$56.24M	$57.15M	$75.22M	$68.18M	$3.80M	$4.39M	$3.35M
Low Forecast	-	-	-	-	-	-	-	-	$173.48M	$1.91M	$56.78M	$51.60M	$56.24M	$57.15M	$75.22M	$68.18M	$2.53M	$2.92M	$2.23M
Surprise %	-	-	-	-	-	-	-	-	-	2.51%	0.07%	0.11%	0.13%	0.10%	0.01%	-	-	-	-

Summit Therapeutics's average Quarter SG&A projection for Dec 23 is $173.48M, based on 1 Wall Street analysts, with a range of $173.48M to $173.48M. The forecast indicates a 2798.98% rise compared to SMMT last annual SG&A of $5.98M (Jun 21).

Summit Therapeutics EPS Forecast

	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 18	Sep 17
# Analysts	-	-	-	-	-	-	-	-	1	7	13	13	7	7	9	8	14	7	11
EPS	-	-	-	-	-	-	-	-	-	$-0.28	$-0.22	$-0.18	$-0.26	$-0.23	$-0.09	-	-	-	-
Avg Forecast	$-0.64	$-0.09	$-0.08	$-0.07	$-0.06	$-0.06	$-0.05	$-0.05	$1.65	$-0.13	$-0.12	$-0.15	$-0.19	$-0.07	$-0.02	$-0.17	$-0.67	$-0.75	$0.30
High Forecast	$-0.64	$-0.09	$-0.08	$-0.07	$-0.06	$-0.06	$-0.05	$-0.05	$1.65	$-0.13	$-0.12	$-0.15	$-0.19	$-0.07	$-0.02	$-0.17	$-0.54	$-0.59	$0.36
Low Forecast	$-0.64	$-0.09	$-0.08	$-0.07	$-0.06	$-0.07	$-0.05	$-0.05	$1.65	$-0.13	$-0.12	$-0.15	$-0.19	$-0.07	$-0.02	$-0.17	$-0.80	$-0.90	$0.24
Surprise %	-	-	-	-	-	-	-	-	-	2.15%	1.79%	1.17%	1.40%	3.19%	4.38%	-	-	-	-

According to undefined Wall Street analysts, Summit Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SMMT previous annual EPS of $NaN (undefined).

Summit Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
NKTX	Nkarta	$2.27	$21.60	851.54%	Buy
ZURA	Zura Bio	$2.51	$10.00	298.41%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
KZR	Kezar Life Sciences	$6.52	$17.50	168.40%	Buy
SMMT	Summit Therapeutics	$18.57	$35.00	88.48%	Buy
KRON	Kronos Bio	$0.96	$1.00	4.17%	Buy

SMMT Forecast FAQ

Is Summit Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, Summit Therapeutics (SMMT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of SMMT's total ratings.

What is SMMT's price target?

Summit Therapeutics (SMMT) average price target is $35 with a range of $23 to $45, implying a 95.86% from its last price of $17.87. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Summit Therapeutics stock go up soon?

According to Wall Street analysts' prediction for SMMT stock, the company can go up by 95.86% (from the last price of $17.87 to the average price target of $35), up by 151.82% based on the highest stock price target, and up by 28.71% based on the lowest stock price target.

Can Summit Therapeutics stock reach $30?

SMMT's average twelve months analyst stock price target of $35 supports the claim that Summit Therapeutics can reach $30 in the near future.

What are Summit Therapeutics's analysts' financial forecasts?

Summit Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-117M (high $-111M, low $-122M), average SG&A $0 (high $0, low $0), and average EPS is $-0.162 (high $-0.154, low $-0.17). SMMT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-221M (high $-221M, low $-221M), average SG&A $0 (high $0, low $0), and average EPS is $-0.305 (high $-0.305, low $-0.305).

Did the SMMT's actual financial results beat the analysts' financial forecasts?

Based on Summit Therapeutics's last annual report (Dec 2020), the company's revenue was $860K, which missed the average analysts forecast of $13.49M by -93.62%. Apple's EBITDA was $-51.475M, missing the average prediction of $-1.481B by -96.52%. The company's net income was $-52.697M, missing the average estimation of $-1.68B by -96.86%. Apple's SG&A was $19.23M, missing the average forecast of $240.21M by -91.99%. Lastly, the company's EPS was $-0.76, beating the average prediction of $-0.433 by 75.49%. In terms of the last quarterly report (Jun 2021), Summit Therapeutics's revenue was $57K, missing the average analysts' forecast of $3.22M by -98.23%. The company's EBITDA was $-23.751M, beating the average prediction of $-9.457M by 151.15%. Summit Therapeutics's net income was $-25.102M, beating the average estimation of $-9.722M by 158.21%. The company's SG&A was $5.98M, beating the average forecast of $2.38M by 151.15%. Lastly, the company's EPS was $-0.28, beating the average prediction of $-0.13 by 114.87%